Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COVID-19 mRNA vaccine (JN.1 strain-compatible)
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The COVID-19 mRNA vaccine (JN.1 strain-compatible) refers to a category of messenger RNA-based vaccines updated to target the SARS-CoV-2 JN.1 variant, a sublineage of the BA.2.86 (Omicron) strain. These vaccines were developed for the 2024–2025 vaccination season following recommendations from global health organizations like the WHO and regulatory agencies such as the FDA and EMA to transition to monovalent JN.1 formulations. The vaccines work by delivering mRNA encapsulated in lipid nanoparticles, which instructs host cells to synthesize the JN.1 spike protein, thereby eliciting a protective immune response including neutralizing antibodies and T-cell activation. Key products in this category include Pfizer/BioNTech's Comirnaty, Moderna's Spikevax, and Daiichi Sankyo's Daichirona, all of which have received regulatory approvals or authorizations for use as boosters or primary series in various jurisdictions.
- Brand names
- ComirnatySpikevaxDaichirona
- Other names
- JN.1-adapted COVID-19 mRNA vaccinemonovalent JN.1 mRNA vaccine2024-2025 COVID-19 mRNA vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)IFIH1 (MDA5)TLR7/8 (Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8))ACE2 (Angiotensin-converting enzyme 2)T-cell receptor (TCR) on CD4+ helper T cells recognizing SARS-CoV-2 JN.1 spike-derived peptides presented by MHC class II
Beyond the preview
Go deeper on COVID-19 mRNA vaccine (JN.1 strain-compatible).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COVID-19 mRNA vaccine (JN.1 strain-compatible).